A detailed history of Jpmorgan Chase & CO transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Jpmorgan Chase & CO holds 53,488 shares of AMRN stock, worth $28,348. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,488
Previous 56,979 6.13%
Holding current value
$28,348
Previous $39,000 15.38%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$0.57 - $0.8 $1,989 - $2,792
-3,491 Reduced 6.13%
53,488 $33,000
Q2 2024

Aug 12, 2024

SELL
$0.63 - $1.07 $25,527 - $43,356
-40,520 Reduced 41.56%
56,979 $39,000
Q1 2024

May 10, 2024

BUY
$0.82 - $1.35 $6,945 - $11,434
8,470 Added 9.51%
97,499 $86,000
Q4 2023

Feb 12, 2024

SELL
$0.66 - $0.91 $1,061 - $1,463
-1,608 Reduced 1.77%
89,029 $77,000
Q3 2023

Nov 14, 2023

BUY
$0.85 - $1.43 $59,522 - $100,137
70,026 Added 339.75%
90,637 $83,000
Q2 2023

Aug 11, 2023

SELL
$1.12 - $1.49 $6,515 - $8,667
-5,817 Reduced 22.01%
20,611 $24,000
Q1 2023

May 11, 2023

SELL
$1.19 - $2.19 $7,326 - $13,483
-6,157 Reduced 18.9%
26,428 $39,000
Q4 2022

Feb 13, 2023

SELL
$1.07 - $1.34 $21,456 - $26,871
-20,053 Reduced 38.1%
32,585 $39,000
Q3 2022

Nov 14, 2022

BUY
$1.09 - $1.67 $3,642 - $5,581
3,342 Added 6.78%
52,638 $57,000
Q2 2022

Aug 11, 2022

SELL
$1.13 - $3.69 $60,597 - $197,879
-53,626 Reduced 52.1%
49,296 $74,000
Q1 2022

May 11, 2022

BUY
$2.85 - $3.73 $21,360 - $27,956
7,495 Added 7.85%
102,922 $339,000
Q4 2021

Feb 10, 2022

SELL
$3.24 - $5.18 $57,940 - $92,633
-17,883 Reduced 15.78%
95,427 $322,000
Q3 2021

Nov 12, 2021

BUY
$3.94 - $5.84 $446,441 - $661,730
113,310 New
113,310 $578,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $214M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.